Eli Lilly Stock (LLY) Gets a Boost From Latest Trial Results. It Has Nothing to Do with Obesity Drugs

FomoAnxiety · 2026-03-27T16:13:18+00:00

Eli Lilly's clinical trial for its eczema treatment, Ebglyss, showed strong long-term results, with significant relief from itching for up to four years. The treatment is safe and effective for patients unable to use topical therapies, and the FDA has received the latest data.

FomoAnxiety

2026-03-27 16:13:18

Abstract generation in progress

Eli Lilly LLY -1.04% ▼ has reported strong results from a clinical trial involving its new medication to treat the eczema skin condition.

Claim 30% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

In the long-term trial, Eli Lilly’s drug showed durable results, providing  relief from persistent  itching for ‌up to four years in patients with eczema. The once-monthly injection of the drug, Ebglyss, was found to help ⁠patients with moderate-to-severe dermatitis, which leads to intense itching and scratching.

The injectable treatment is aimed at adults and children 12 years and older with moderate-to-severe eczema who cannot use topical therapies. In the study, the majority of patients achieved near-complete skin clearance and itch relief with up to four years of continuous treatment, said Eli Lilly ‌in a news release.

Eli Lilly’s Drug Pipeline

Ebglyss was also found to ⁠be safe for patients regardless of dosing frequency, and no new safety issues were observed in the clinical trial, according to Eli Lilly. The current trial will continue for another year as it seeks to look at five-year treatment results in patients.

Eli Lilly said it has submitted ⁠the latest trial data to the U.S. Food and Drug Administration (FDA). While Eli Lilly is mostly associated with its weight-loss medications, the company has a robust pipeline of drug candidates that treat diseases ranging from Alzheimer’s to cancer.

Is LLY Stock a Buy?

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last three months. The average LLY price target of $1,247.38 implies 31.53% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes